Dasatinib Dyronib Dasatinib

Dasatinib is an oral Bcr-Abl tyrosine kinase inhibitor (inhibiting the "Philadelphia chromosome") and Src family tyrosine kinase inhibitor approved for first-line use in chronic myelogenous leukemia (CML) and Philadelphia chromosome-positive acute lymphoblastic leukemia (PH+ ALL). It is being evaluated for use in a number of other cancers, including advanced prostate cancer.